8-K Announcements
6Material company update
Mar 5, 2026·SEC
Material company update
Feb 3, 2026·SEC
Material company update
Jan 28, 2026·SEC
Altimmune, Inc.(ALT)Earnings, Financials & Key Ratios
ALT•NASDAQ
$3.26
$361M mkt cap·Price updated May 6, 2026
AboutAltimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.Show more
- Revenue$41K+105.0%
- EBITDA-$94M+8.2%
- Net Income-$88M+7.3%
- EPS (Diluted)-1.00+25.4%
- EBITDA Margin-230460.98%+55.2%
- Operating Margin-230460.98%+55.3%
- Net Margin-214860.98%+54.8%
- ROE-50.57%+15.5%
- ROIC-46.67%+55.4%
- Debt/Equity0.15+1020.2%
- Interest Coverage-57.76+99.5%
ALT Key Insights
Altimmune, Inc. (ALT) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Trading at only 1.3x book value
✗Weaknesses
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 12 (bottom 12%)
- ✗Sales declining 65.3% over 5 years
- ✗Shares diluted 24.1% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
ALT Price & Volume
Altimmune, Inc. (ALT) stock price & volume — 10-year historical chart
Loading chart...
ALT Growth Metrics
Altimmune, Inc. (ALT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-42.64%
5 Years-65.33%
3 Years-
TTM105%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM7.33%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM24.63%
Return on Capital
10 Years-60.14%
5 Years-50.01%
3 Years-53.48%
Last Year-47.99%
ALT Recent Earnings
Altimmune, Inc. (ALT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 10/12 qtrs (100%)
Q2 2026Latest
Mar 5, 2026EPS
$0.27
Est $0.25
-8.0%
Revenue
$26,000
Est $556
+4576.3%
Q4 2025
Nov 6, 2025EPS
$0.21
Est $0.29
+27.6%
Revenue
$5,000
Est $560
+792.9%
Q3 2025
Aug 12, 2025EPS
$0.27
Est $0.32
+15.6%
Revenue
$5,000
Est $1,429
+249.9%
Q2 2025
May 13, 2025EPS
$0.26
Est $0.35
+25.7%
Revenue
$5,000
Est $560
+792.9%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 5, 2026 | $0.27vs $0.25-8.0% | $26,000vs $556+4576.3% |
| Q4 2025 | Nov 6, 2025 | $0.21vs $0.29+27.6% | $5,000vs $560+792.9% |
| Q3 2025 | Aug 12, 2025 | $0.27vs $0.32+15.6% | $5,000vs $1,429+249.9% |
| Q2 2025 | May 13, 2025 | $0.26vs $0.35+25.7% | $5,000vs $560+792.9% |
Based on last 12 quarters of dataView full earnings history →
ALT Peer Comparison
Altimmune, Inc. (ALT) competitors in Metabolic and Obesity Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 VKTX | 3.74B | 32.28 | -10.12 | -71.31% | 0.00 | |||
 TERN | 4.64B | 52.97 | -47.29 | -29.95% | 0.00 | |||
 NRXP | 84.43M | 3.05 | -2.28 | -157.28% | ||||
 GPCR | 2.35B | 40.84 | -17.02 | -14.55% | 0.00 | |||
 ELVN | 2.45B | 41.20 | -22.51 | -24.22% | ||||
 MDGL | 12.38B | 539.73 | -42.00 | 432.05% | -27.32% | -50.15% | 0.59 | |
 AKRO | 4.5B | 54.65 | -14.57 | -30.58% | 0.05 | |||
 HALO | 7.81B | 66.35 | 25.92 | 37.55% | 22.69% | 6.49% |
Compare ALT vs Peers
Altimmune, Inc. (ALT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ALT Income Statement
Altimmune, Inc. (ALT) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 41.5K | 10.33M | 5.8M | 8.19M | 4.41M | -68K | 426K | 20K | 41K |
| Revenue Growth % | -99.21% | 24792.58% | -43.85% | 41.09% | -46.12% | -101.54% | 726.47% | -95.31% | 105% |
| Cost of Goods Sold | 18.41M | 18.46M | 0 | 33.51M | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | 44349.39% | 178.68% | - | 409.4% | - | - | - | - | - |
| Gross Profit | -18.36M▲ 0% | -8.13M▲ 55.7% | 5.8M▲ 171.4% | -25.32M▼ 536.5% | 4.41M▲ 117.4% | -68K▼ 101.5% | 426K▲ 726.5% | 20K▼ 95.3% | 0▼ 100.0% |
| Gross Margin % | -44249.39% | -78.68% | 100% | -309.4% | 100% | 100% | 100% | 100% | - |
| Gross Profit Growth % | -822.27% | 55.74% | 171.37% | -536.52% | 117.41% | -101.54% | 726.47% | -95.31% | -100% |
| Operating Expenses | 16.17M | 28.22M | 27.27M | 29.47M | 101.32M | 87.67M | 96.36M | 103.19M | 94.53M |
| OpEx % of Revenue | 38953.97% | 273.2% | 470% | 360.1% | 2297.6% | -128929.41% | 22618.54% | 515960% | 230560.98% |
| Selling, General & Admin | 8.46M | 9.77M | 8.5M | 13.21M | 15.41M | 17.13M | 18.14M | 20.97M | 28.1M |
| SG&A % of Revenue | 20378.18% | 94.53% | 146.53% | 161.39% | 349.5% | -25197.06% | 4257.51% | 104830% | 68531.71% |
| Research & Development | 18.41M | 18.46M | 17.77M | 49.77M | 74.54M | 70.54M | 65.8M | 82.23M | 66.43M |
| R&D % of Revenue | 44349.39% | 178.68% | 306.23% | 608.11% | 1690.27% | -103732.35% | 15445.77% | 411130% | 162029.27% |
| Other Operating Expenses | 5.67K | 277.89K | 1M | -33.51M | 11.37M | 0 | 12.42M | 0 | 0 |
| Operating Income | -52.05M▲ 0% | -42.83M▲ 17.7% | -21.46M▲ 49.9% | -54.8M▼ 155.3% | -96.91M▼ 76.9% | -87.74M▲ 9.5% | -95.93M▼ 9.3% | -103.17M▼ 7.6% | -94.49M▲ 8.4% |
| Operating Margin % | -125401.2% | -414.61% | -370% | -669.5% | -2197.6% | 129029.41% | -22518.54% | -515860% | -230460.98% |
| Operating Income Growth % | -362.04% | 17.7% | 49.89% | -155.29% | -76.85% | 9.47% | -9.33% | -7.55% | 8.42% |
| EBITDA | -51.91M | -42.53M | -21.08M | -54.37M | -96.36M | -87.25M | -95.45M | -102.93M | -94.49M |
| EBITDA Margin % | -125066.24% | -411.69% | -363.32% | -664.26% | -2185.1% | 128304.41% | -22406.57% | -514670% | -230460.98% |
| EBITDA Growth % | -366.41% | 18.06% | 50.44% | -157.95% | -77.24% | 9.46% | -9.4% | -7.84% | 8.2% |
| D&A (Non-Cash Add-back) | 139.02K | 302.37K | 387.32K | 428.88K | 551K | 493K | 477K | 238K | 0 |
| EBIT | -51.9M | -45.02M | -20.58M | -38.53M | -97.08M | -84.9M | -88.41M | -95.05M | -94.49M |
| Net Interest Income | -114.56K | -70.49K | 841.16K | 313.09K | 198K | 2.86M | 7.32M | 8.06M | 5.91M |
| Interest Income | 47.58K | 226.6K | 843.41K | 322.51K | 203K | 2.87M | 7.35M | 8.07M | 7.54M |
| Interest Expense | 162.14K | 297.09K | 2.24K | 9.42K | 5K | 8K | 35K | 9K | 1.64M |
| Other Income/Expense | -18.51K | -2.49M | 886.3K | 11.17M | -176K | 2.83M | 7.48M | 8.11M | 5.71M |
| Pretax Income | -52.06M▲ 0% | -45.32M▲ 13.0% | -20.58M▲ 54.6% | -43.63M▼ 112.0% | -97.09M▼ 122.5% | -84.91M▲ 12.5% | -88.45M▼ 4.2% | -95.06M▼ 7.5% | -88.77M▲ 6.6% |
| Pretax Margin % | -125445.79% | -438.68% | -354.72% | -533.02% | -2201.59% | 124867.65% | -20762.21% | -475295% | -216521.95% |
| Income Tax | -5.64M | -6.15M | -58.5K | 5.42M | 0 | -197K | 0 | 0 | -681K |
| Effective Tax Rate % | 10.83% | 13.57% | 0.28% | -12.42% | 0% | 0.23% | 0% | 0% | 0.77% |
| Net Income | -46.43M▲ 0% | -39.17M▲ 15.6% | -20.52M▲ 47.6% | -49.04M▼ 139.0% | -97.09M▼ 98.0% | -84.71M▲ 12.7% | -88.45M▼ 4.4% | -95.06M▼ 7.5% | -88.09M▲ 7.3% |
| Net Margin % | -111860.32% | -379.16% | -353.71% | -599.2% | -2201.59% | 124577.94% | -20762.21% | -475295% | -214860.98% |
| Net Income Growth % | -123.95% | 15.63% | 47.61% | -139.01% | -97.96% | 12.75% | -4.41% | -7.48% | 7.33% |
| Net Income (Continuing) | -46.43M | -39.17M | -20.52M | -49.04M | -97.09M | -84.71M | -88.45M | -95.06M | -88.09M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -108.77▲ 0% | -13.98▲ 87.1% | -1.56▲ 88.8% | -1.91▼ 22.4% | -2.35▼ 23.0% | -1.81▲ 23.0% | -1.66▲ 8.3% | -1.34▲ 19.3% | -1.00▲ 25.4% |
| EPS Growth % | -118.41% | 87.15% | 88.84% | -22.44% | -23.04% | 22.98% | 8.29% | 19.28% | 25.37% |
| EPS (Basic) | -108.77 | -13.98 | -1.56 | -1.91 | -2.35 | -1.81 | -1.66 | -1.34 | -1.00 |
| Diluted Shares Outstanding | 426.83K | 2.8M | 13.12M | 25.64M | 41.28M | 46.93M | 53.25M | 71M | 88.1M |
| Basic Shares Outstanding | 426.83K | 2.8M | 13.12M | 25.64M | 41.28M | 46.93M | 53.25M | 71M | 88.1M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
ALT Balance Sheet
Altimmune, Inc. (ALT) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 23.47M | 39.37M | 39.39M | 230.26M | 204.13M | 192.81M | 209.63M | 137.25M | 278.19M |
| Cash & Short-Term Investments | 8.77M | 33.72M | 37.24M | 215.92M | 190.3M | 184.88M | 197.81M | 131.89M | 273.46M |
| Cash Only | 8.77M | 33.72M | 8.96M | 115.92M | 190.3M | 111.1M | 135.12M | 36.93M | 43.76M |
| Short-Term Investments | 0 | 0 | 28.28M | 100.01M | 0 | 73.78M | 62.7M | 94.97M | 229.7M |
| Accounts Receivable | 10.17M | 4.47M | 1.65M | 12.37M | 5.84M | 2.54M | 4.85M | 3.12M | 1.22M |
| Days Sales Outstanding | 89.42K | 157.96 | 103.83 | 551.76 | 483.27 | -13.64K | 4.16K | 56.89K | 10.85K |
| Inventory | 3.53M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | 70.08 | - | - | - | - | - | - | - | - |
| Other Current Assets | 3.53M | 634.42K | 34.17K | 34.17K | 33.31K | 5.39M | 6.96M | 2.25M | 3.52M |
| Total Non-Current Assets | 39.56M | 15.38M | 14.66M | 14.86M | 14.74M | 14.12M | 1.01M | 2.05M | 1.74M |
| Property, Plant & Equipment | 603.15K | 1.34M | 1.8M | 1.96M | 1.45M | 1.08M | 651K | 413K | 312K |
| Fixed Asset Turnover | 0.07x | 7.69x | 3.22x | 4.17x | 3.05x | -0.06x | 0.65x | 0.05x | 0.13x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 38.72M | 13.85M | 12.73M | 12.82M | 12.42M | 12.42M | 0 | 0 | 0 |
| Long-Term Investments | -5.94B | -58.5M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 238.92K | 183.68K | 128.55K | 73.41K | 872K | 615K | 363K | 1.64M | 1.43M |
| Total Assets | 63.03M▲ 0% | 54.75M▼ 13.1% | 54.06M▼ 1.3% | 245.12M▲ 353.4% | 218.87M▼ 10.7% | 206.93M▼ 5.5% | 210.64M▲ 1.8% | 139.31M▼ 33.9% | 279.93M▲ 100.9% |
| Asset Turnover | 0.00x | 0.19x | 0.11x | 0.03x | 0.02x | -0.00x | 0.00x | 0.00x | 0.00x |
| Asset Growth % | -71.95% | -13.14% | -1.26% | 353.43% | -10.71% | -5.45% | 1.79% | -33.87% | 100.95% |
| Total Current Liabilities | 3.84M | 4.53M | 3.92M | 12.02M | 18.28M | 17.05M | 12.14M | 10.47M | 15M |
| Accounts Payable | 129.07K | 372.86K | 18.23K | 612.29K | 2.03M | 4.8M | 2.07M | 211K | 2.72M |
| Days Payables Outstanding | 2.56 | 7.37 | - | 6.67 | - | - | - | - | - |
| Short-Term Debt | 49.7K | 71.6K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 19.75K | 19.75K | 61.56K | 19.75K | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.9M | 2.81M | 0 | 8.68M | 6.09M | 0 | 0 | 0 | 12.28M |
| Current Ratio | 6.11x | 8.70x | 10.04x | 19.16x | 11.17x | 11.31x | 17.26x | 13.11x | 18.55x |
| Quick Ratio | 5.19x | 8.70x | 10.04x | 19.16x | 11.17x | 11.31x | 17.26x | 13.11x | 18.55x |
| Cash Conversion Cycle | 89.49K | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 10.51M | 1.91M | 4.61M | 7.22M | 1.45M | 4.58M | 4.4M | 5.33M | 40.04M |
| Long-Term Debt | 599.93K | 501.17K | 0 | 0 | 0 | 0 | 0 | 0 | 34.29M |
| Capital Lease Obligations | 0 | 0 | 1.48M | 1.47M | 1.12M | 672K | 175K | 1.4M | 0 |
| Deferred Tax Liabilities | 5.94M | 58.5K | 0 | -250K | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 3.81M | 1.35M | 2.88M | 5.75M | 330K | 3.91M | 4.22M | 3.93M | 5.75M |
| Total Liabilities | 14.35M | 6.44M | 8.54M | 19.24M | 19.73M | 21.64M | 16.54M | 15.8M | 55.04M |
| Total Debt | 49.7K | 572.77K | 1.74M | 1.82M | 1.53M | 1.12M | 671K | 1.68M | 34.29M |
| Net Debt | -8.72M | -33.15M | -7.22M | -114.09M | -188.77M | -109.97M | -134.45M | -35.24M | -9.47M |
| Debt / Equity | 0.00x | 0.01x | 0.04x | 0.01x | 0.01x | 0.01x | 0.00x | 0.01x | 0.15x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -320.99x | -144.18x | -9565.48x | -5816.66x | -19382.80x | -10967.50x | -2740.83x | -11463.56x | -57.76x |
| Total Equity | 48.68M▲ 0% | 48.31M▼ 0.7% | 45.52M▼ 5.8% | 225.88M▲ 396.2% | 199.13M▼ 11.8% | 185.29M▼ 7.0% | 194.1M▲ 4.8% | 123.51M▼ 36.4% | 224.89M▲ 82.1% |
| Equity Growth % | 150.15% | -0.75% | -5.78% | 396.21% | -11.84% | -6.95% | 4.75% | -36.37% | 82.09% |
| Book Value per Share | 114.04 | 17.24 | 3.47 | 8.81 | 4.82 | 3.95 | 3.65 | 1.74 | 2.55 |
| Total Shareholders' Equity | 48.68M | 48.31M | 45.52M | 225.88M | 199.13M | 185.29M | 194.1M | 123.51M | 224.89M |
| Common Stock | 1.81K | 876 | 1.51K | 3.7K | 4K | 5K | 7K | 7K | 11K |
| Retained Earnings | -77.68M | -116.86M | -137.38M | -186.42M | -293.17M | -377.88M | -466.33M | -561.39M | -649.48M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -4.58M | -5.04M | -5.02M | -5.04M | -5.04M | -5.23M | -5M | -4.97M | -4.93M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ALT Cash Flow Statement
Altimmune, Inc. (ALT) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -20.21M | -9.39M | -9.6M | -34.31M | -78.24M | -62.59M | -75.81M | -79.85M | -67.53M |
| Operating CF Margin % | -48705.1% | -90.88% | -165.51% | -419.13% | -1774.1% | 92038.24% | -17795.77% | -399240% | -164719.51% |
| Operating CF Growth % | -110.03% | 53.55% | -2.27% | -257.28% | -128.06% | 20.01% | -21.13% | -5.33% | 15.42% |
| Net Income | -46.43M | -39.17M | -20.52M | -49.04M | -97.09M | -84.71M | -88.45M | -95.06M | -88.09M |
| Depreciation & Amortization | 139.02K | 302.37K | 387.32K | 428.88K | 551K | 493K | 477K | 238K | 112K |
| Stock-Based Compensation | 1.44M | 773.25K | 0 | 2.58M | 5.52M | 8.1M | 10.64M | 14.39M | 16.08M |
| Deferred Taxes | -2.62B | -6.15M | -58.5K | 0 | 0 | 0 | 0 | 0 | -681K |
| Other Non-Cash Items | 2.65B | 27.88M | 8.77M | 16.25M | 13.03M | -578K | 9.79M | -3.9M | 5.05M |
| Working Capital Changes | -11.31M | 6.98M | 1.82M | -4.51M | -251K | 14.11M | -8.27M | 4.48M | 0 |
| Change in Receivables | -1.95M | 344.3K | 2.82M | -10.72M | 6.53M | 3.3M | -2.31M | 1.74M | -675K |
| Change in Inventory | -4.12M | 5.59M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -2.62M | 243.06K | -354.63K | 594.06K | 1.42M | 2.77M | -2.73M | -1.86M | 2.51M |
| Cash from Investing | 13.73M | -1M | -28.29M | -72.23M | 87.52M | -73.4M | 13.73M | -28.39M | -132.47M |
| Capital Expenditures | -166.33K | -1.02M | -29K | -203.96K | -12.12M | -126K | -47K | 0 | -11K |
| CapEx % of Revenue | 400.76% | 9.83% | 0.5% | 2.49% | 274.76% | -185.29% | 11.03% | - | 26.83% |
| Acquisitions | 13.68M | 14.49K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 207.63K | 14.49K | 0 | -138.46K | -195K | 0 | 0 | 0 | 0 |
| Cash from Financing | 15.84M | 32.49M | 12.53M | 213.49M | 65.1M | 56.78M | 86.11M | 10.04M | 206.84M |
| Debt Issued (Net) | 2.81M | -1.55M | -292K | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | -2.39M | 0 | 0 | 0 | 0 | 0 | 0 | 291K |
| Other Financing | 16.45K | -977.1K | 125K | 41.17M | 58K | 434K | -496K | 50K | 206.84M |
| Net Change in Cash | 9.43M▲ 0% | 22.05M▲ 133.9% | -25.36M▼ 215.0% | 106.96M▲ 521.8% | 74.38M▼ 30.5% | -79.2M▼ 206.5% | 24.03M▲ 130.3% | -98.19M▼ 508.7% | 6.83M▲ 107.0% |
| Free Cash Flow | -20.38M▲ 0% | -10.4M▲ 48.9% | -9.6M▲ 7.7% | -34.65M▼ 260.8% | -90.55M▼ 161.3% | -62.71M▲ 30.7% | -75.86M▼ 21.0% | -79.85M▼ 5.3% | -67.55M▲ 15.4% |
| FCF Margin % | -49105.86% | -100.71% | -165.53% | -423.31% | -2053.29% | 92223.53% | -17806.81% | -399240% | -164746.34% |
| FCF Growth % | -110.12% | 48.95% | 7.7% | -260.8% | -161.34% | 30.74% | -20.96% | -5.26% | 15.41% |
| FCF per Share | -47.75 | -3.71 | -0.73 | -1.35 | -2.19 | -1.34 | -1.42 | -1.12 | -0.77 |
| FCF Conversion (FCF/Net Income) | 0.44x | 0.24x | 0.47x | 0.70x | 0.81x | 0.74x | 0.86x | 0.84x | 0.77x |
| Interest Paid | 0 | 0 | 0 | 1.79K | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ALT Key Ratios
Altimmune, Inc. (ALT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | 1073.74% | -136.27% | -80.77% | -43.74% | -36.14% | -45.69% | -44.07% | -46.63% | -59.86% | -50.57% |
| Return on Invested Capital (ROIC) | - | -97.69% | -116.56% | -60.22% | -54.77% | -119.01% | -153.59% | -106.61% | -104.63% | -46.67% |
| Gross Margin | -38.07% | -44249.39% | -78.68% | 100% | -309.4% | 100% | 100% | 100% | 100% | - |
| Net Margin | 3706.44% | -111860.32% | -379.16% | -353.71% | -599.2% | -2201.59% | 124577.94% | -20762.21% | -475295% | -214860.98% |
| Debt / Equity | 0.05x | 0.00x | 0.01x | 0.04x | 0.01x | 0.01x | 0.01x | 0.00x | 0.01x | 0.15x |
| Interest Coverage | -292.59x | -320.99x | -144.18x | -9565.48x | -5816.66x | -19382.80x | -10967.50x | -2740.83x | -11463.56x | -57.76x |
| FCF Conversion | 1.04x | 0.44x | 0.24x | 0.47x | 0.70x | 0.81x | 0.74x | 0.86x | 0.84x | 0.77x |
| Revenue Growth | -50.85% | -99.21% | 24792.58% | -43.85% | 41.09% | -46.12% | -101.54% | 726.47% | -95.31% | 105% |
ALT SEC Filings & Documents
Altimmune, Inc. (ALT) SEC filings — annual & quarterly reports (10-K, 10-Q)
ALT Frequently Asked Questions
Altimmune, Inc. (ALT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Altimmune, Inc. (ALT) reported $0.0M in revenue for fiscal year 2025. This represents a 93% decrease from $0.6M in 2005.
Altimmune, Inc. (ALT) grew revenue by 105.0% over the past year. This is strong growth.
Altimmune, Inc. (ALT) reported a net loss of $88.1M for fiscal year 2025.
Dividend & Returns
Altimmune, Inc. (ALT) has a return on equity (ROE) of -50.6%. Negative ROE indicates the company is unprofitable.
Altimmune, Inc. (ALT) had negative free cash flow of $67.8M in fiscal year 2025, likely due to heavy capital investments.
Explore More ALT
Altimmune, Inc. (ALT) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates